Essex Investment Management Co. LLC lowered its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 63.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,274 shares of the biopharmaceutical company’s stock after selling 52,477 shares during the quarter. Essex Investment Management Co. LLC owned approximately 0.08% of ProQR Therapeutics worth $586,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in PRQR. Millennium Management LLC acquired a new position in ProQR Therapeutics during the 2nd quarter valued at approximately $1,426,000. Ardsley Advisory Partners acquired a new position in ProQR Therapeutics during the 2nd quarter valued at approximately $365,000. Jennison Associates LLC boosted its position in ProQR Therapeutics by 1.0% during the 2nd quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock valued at $21,763,000 after purchasing an additional 30,831 shares during the period. Franklin Street Advisors Inc. NC boosted its position in ProQR Therapeutics by 50.0% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $657,000 after purchasing an additional 30,000 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in ProQR Therapeutics by 519.0% during the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 28,025 shares during the period. Institutional investors and hedge funds own 28.65% of the company’s stock.
Shares of PRQR stock opened at $19.25 on Friday. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.26. ProQR Therapeutics NV has a 1 year low of $2.75 and a 1 year high of $22.85. The firm has a market cap of $712.74 million, a price-to-earnings ratio of -9.92 and a beta of 0.44.
ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.15. Equities analysts expect that ProQR Therapeutics NV will post -1.38 EPS for the current year.
A number of research analysts recently issued reports on PRQR shares. Zacks Investment Research lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 13th. ValuEngine lowered ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 30th. Evercore ISI assumed coverage on ProQR Therapeutics in a research report on Tuesday, September 18th. They set an “outperform” rating and a $35.00 price target for the company. HC Wainwright reiterated a “buy” rating on shares of ProQR Therapeutics in a research report on Monday, July 2nd. Finally, Chardan Capital reiterated a “buy” rating and set a $9.00 price target on shares of ProQR Therapeutics in a research report on Monday, August 13th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $18.00.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Read More: Growth Stocks, What They Are, What They Are Not
Want to see what other hedge funds are holding PRQR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProQR Therapeutics NV (NASDAQ:PRQR).
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.